ACHV Achieve Life Sciences Inc.

3.68
+0.14  (+4%)
Previous Close 3.54
Open 3.48
Price To Book 1.57
Market Cap 24734016
Shares 6,721,200
Volume 60,288
Short Ratio
Av. Daily Volume 2,064,592

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due mid-2019.
Cytisine
Smoking cessation

Latest News

  1. Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
  2. The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
  3. Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
  4. ACHV: Fiscal Year 2018 Operational and Financial Results
  5. What Do the Clinical Updates at Achieve Life Sciences Mean for Cytisinicline
  6. Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
  7. Four Healthcare Stocks Picking Up Speed On Friday
  8. Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
  9. ACHV: A Reason to Quit is a Reason to Buy
  10. Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019
  11. Predictive Technology Group Names Jay M. Moyes to Its Board of Directors
  12. Healthcare Stocks Leading the Sector
  13. Could The Achieve Life Sciences, Inc. (NASDAQ:ACHV) Ownership Structure Tell Us Something Useful?
  14. Four Healthcare Stocks Looking to Close Out a Strong Week
  15. Achieve Life Sciences' stock rockets on heavy volume after update results of smoking-cessation drug trial
  16. Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting
  17. Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation
  18. 5 Top Rising P/E Stocks to Enjoy Solid Gains
  19. Achieve Announces Update on Cytisinicline Clinical Development Program
  20. Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals